ACY 001

Drug Profile

ACY 001

Alternative Names: ACY001; Stem cell therapy-Ischaemia - Arteriocyte

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Arteriocyte
  • Developer Arteriocyte; Cleveland Clinic Cole Eye Institute
  • Class Anti-ischaemics; Ischaemic heart disorder therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic retinopathy; Ischaemic heart disorders; Peripheral vascular disorders

Most Recent Events

  • 12 Dec 2016 Arteriocyte is now called Compass Biomedical
  • 02 Apr 2013 Arteriocyte plans a phase II trial for Ischaemic heart disorders in USA
  • 21 Jan 2011 Discontinued - Preclinical for Diabetic retinopathy in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top